# Financial Relationships Disclosures Planners, Faculty, and Other

|  |  |  |  |
| --- | --- | --- | --- |
| **To be completed by education staff.** |  |  | **Individual’s prospective role(s) in education** |
| Name of Individual: | Identify the prospective role(s) that this person may have in the planning and delivery of this education *(choose all that apply)* |
| **Joseph R. Biggio** |  |  | Planner*Examples: planning committee, staff involved in choosing topics, faculty, or content* |
| Title of Continuing Education: |  | **X** | Teacher, Instructor, Faculty |
| **Dept. of Ob/Gyn Grand Rounds Lecture** |  |  | Author, Writer |
| Date and location of Education: |  |  | Reviewer |
| **/ DHLRI Rm 170 & via Microsoft Teams** |  |  | Other  |

|  |
| --- |
| As a prospective planner or faculty member, we would like to ask for your help in protecting our learning environment from industry influence. Please complete the form below and return it to Brian Ehrlich/ CCME by 12/17/2021.DateThe ACCME Standards for Integrity and Independence require that we disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education. Thank you for your diligence and assistance. If you have questions, please contact us at brian.ehrlich@osumc.edu. |
| ***To be Completed by Planner, Faculty, or Others Who May Control Educational Content***Please disclose **all financial relationships** that you have had in the past 24 months with ineligible companies (see definition below).For each financial relationship, enter the name of the ineligible company and the nature of the financial relationship(s). There is no minimum financial threshold; we ask that you disclose all financial relationships, regardless of the amount, with ineligible companies. You should disclose all financial relationships regardless of the potential relevance of each relationship to the education. |
| **Enter the Name of Ineligible Company****An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.****For specific examples of ineligible companies, visit** [**www.accme.org/standards**](http://www.accme.org/standards) **.** | **Enter the Nature of Financial Relationship**Examples of financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed; diversified mutual funds do not need to be disclosed.Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individual’s institution receives the research grant and manages the funds. | **Has the Relationship Ended?**If the financial relationship existed during the last 24 months, but has now ended, please check the box in this column. This will help the education staff determine if any mitigation steps need to be taken. |
| Example: ABC Company | Consultant | **X** |
| Mirvie | Research |  |
| Sera | Research |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  In the past 24 months, I have not had **any** financial relationships with any ineligible companies. |
| **I attest that the above information is correct as of this date of submission.** |  |
| *Speaker Guidelines - Your signature attests to the accuracy of the information you have provided above; as well as agreeing to the following statements:*1. *Your presentation is your original work or a sourced work from a peer, not a prepared presentation from a commercial interest.*
2. *If you discuss a commercial product or device, you must give a balanced view of other therapeutic options.*
3. *The content of your presentation does not promote the proprietary interests of any commercial interests.*
4. *You have read the objectives and have formulated your presentation to best achieve the desired changes in competency, and/or performance improvements and/or patient outcomes.*
5. *Your presentation is in compliance with ACCME®’s content validity value statements.*
6. *Commercial logos must be removed.*
7. *When a commercial product or device is named, the use of the scientific name rather than the commercial name is preferred. It is ultimately up to the presenter to use the terminology that best gets across the message but least appears as an endorsement.*

*Having an interest or affiliation with a corporate organization does not necessarily prevent you from participating in this CME activity. However, CCME policies describe procedures for resolving conflicts of interest that may require reviewing a speaker’s presentation material or limiting the role and input of any person judged to have a conflict.* |



\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_2/6/23\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

signature Date